Malpractices Adopted by Researchers in Good Laboratory Practice (GLP)
Abstract
Good Laboratory Practice (GLP) sets the standard for laboratory safety, quality, and integrity, yet malpractices among researchers can compromise these objectives. This article investigates common malpractices in GLP environments, emphasizing the prevalence and impact of these unethical behaviors. Key issues include data fabrication, falsification, and selective reporting, which undermine scientific credibility and can lead to harmful public health implications. Additionally, poor documentation practices and inadequate staff training exacerbate these problems, allowing deviations from standard procedures to go undetected. The misuse of GLP principles not only skews research outcomes but also affects regulatory decisions and public trust in scientific findings. This paper also highlights the systemic factors contributing to these malpractices, such as pressure to publish, lack of oversight, and inadequate ethical training. To combat these issues, robust measures including stringent auditing, comprehensive training programs, and a culture of integrity and transparency in research are recommended. Addressing these malpractices is crucial for maintaining the high standards expected in GLP and ensuring thereliability of scientific research.
How to cite this article:
Ahmed S. Malpractices Adopted by Researchers
in Good Laboratory Practice (GLP). J Durg Dis Dev
2024; 8(1): 18-25.
References
O. f. E. C.-o. a. D. (OECD)., OECD Principles of Good
Laboratory Practice (GLP), 1998.
U. S. E. P. A. (EPA), Good Laboratory Practice Standards,
E. M. A. (EMA), “Good Laboratory Practice (GLP),” 2012.
W. H. O. (WHO), “Handbook: Good Laboratory Practice
(GLP),” 2009.
OECD, “OECD series on principles of good laboratory
practice and compliance monitoring,” OECD Publishing,
FDA, “Good laboratory practice for nonclinical
laboratory studies,” U.S. Food and Drug Administration,
E. Commission, “Principles of good laboratory practice
and compliance monitoring.,” 1997.
M. &. T. T. N. Rowland, “Clinical pharmacokinetics
and pharmacodynamics: concepts and applications,”
Lippincott Williams & Wilkins, 2010.
O. K. M. &. S. T. Kuhlmann, “Handbook of nonclinical
drug metabolism,” CRC Press, 2014.
J. E. &. J. A. Stiglitz, “The anatomy of a murder: Who
killed America’s economy?,” New Press, 2010.
F. &. S. M. Black, “The pricing of options and corporate
liabilities,” Journal of Political Economy, vol. 81(3), pp.
-654, 1973.
R. A. Posner, “Theories of economic regulation,” The
Bell Journal of Economics and Management Science,
vol. 5(2), pp. 335-358, 1974.
OECD, “Competition Law and Policy in Latin America,”
OECD Publishing, 2017 .
F. S. Board, “Key Attributes of Effective Resolution
Regimes for Financial Institutions,” Financial Stability
Board, 2017.
Martinson, B. C., et al., “Scientists behaving badly,”
Nature, vol. 435(7043), pp. 737-738, 2005.
Vasilevsky, U., et al., “Research misconduct and data
fraud in clinical trials: prevalence and causal factors,”
International Journal of Clinical Pharmacy, vol. 40(6),
pp. 1322-1328, 2018.
D. L. Vaux, “Research methods: Know when your
numbers are significant,” Nature, vol. 531(7596), pp.
-123, 2016.
N. H. Steneck, “Fostering integrity in research:
Definitions, current knowledge, and future directions.,”
Science and Engineering Ethics, vol. 12(1), pp. 53-74,
M. S. R. E. A. D. V. R. &. M. B. C. Anderson, “The
perverse effects of competition on scientists’ work
and relationships,” Science and Engineering Ethics,
vol. 13(4), p. 437–461, 2007.
B. C. A. M. S. &. D. V. R. Martinson, “Scientists behaving
badly,” Nature, vol. 435(7043), p. 737–738, 2005.
N. H. Steneck, “Fostering integrity in research:
Definitions, current knowledge, and future directions.,”
Science and Engineering Ethics, vol. 12(1), p. 53–74,
O. f. E. C.-o. a. D. (OECD), “OECD Principles of GoodLaboratory Practice (as revised in 1997),” 2018.
U. F. a. D. Administration, “Good Laboratory Practice for
Nonclinical Laboratory Studies (21 CFR Part 58),” 2017.
E. M. A. (EMA), “Guideline on Good Pharmacovigilance
Practices (GVP),” 2017.
N. I. o. E. H. S. (NIEHS), “GLP Questions & Answers,”
“OECD Principles of Good Laboratory Practice (GLP),”
OECD Series on Principles of Good Laboratory Practice
and Compliance Monitoring, No. 1., 2018.
U. F. a. D. A. (FDA), “Good Laboratory Practice (GLP)
Regulations,” 2020.
N. I. o. E. H. S. (NIEHS), “Good Laboratory Practice for
Nonclinical Laboratory Studies (GLP),” 2017.
U. F. a. D. Administration, “Good Laboratory Practice
for Nonclinical Laboratory Studies,” vol. 58, p. 21, 2016.
G. L. P. R. U.S. FDA, vol. 58, p. 21 , 2016.
S. P. Turner, “Good Laboratory Practice Regulations.”
Handbook of Laboratory Animal Science, Volume III:
Animal Models and Research Designs,” CRC Press, 2021.
L. V. &. M. H. Nardelli, “Safety in the Laboratory: A New
Culture of Prevention.,” Journal of Chemical Health
and Safety, vol. 26(4), pp. 5-12, 2019.
S. R. &. S. S. G. Beck, “Standard Operating Procedures: A
Practical Guide to Good Practice,” American Journal of
Health-System Pharmacy, vol. 75(2), pp. 101-110, 2018.
J. A. Kovacs, “Reproducibility in Scientific Research,”
Nature Biotechnology, vol. 36(6), pp. 562-564, 2018.
F. Gannon, “The Ethical Implications of Research
Misconduct,” EMBO Reports, vol. 15(2), pp. 129-132,
B. Barnes, “Reproducibility: The risks of the replication
drive,” Nature, vol. 528(7582), pp. 479-481, 2015.
S. N. F. D. &. I. J. P. Goodman, “What does research
reproducibility mean?,” Science Translational Medicine,
vol. 8(341), pp. 12-34, 2016.
B. A. A. G. B. G. C. B. D. B. S. D. B. S. J. .. &. C. M. Nosek,
“Promoting an open research culture,” Science, Vols.
-1425, p. 348(6242), 2015.
Vedula, S. S., et al. , “Assessment of the prevalence of
unreported clinical trial outcomes among published
trials of oncology interventions.,” JAMA Oncology, vol.
(4), pp. 455-461, 2015.
L. P. e. a. Freedman, “The economics of reproducibility
in preclinical research,” PLoS Biology, vol. 13(6), p.
e1002165, 2015.
D. SS, “Good laboratory practice: a tool for global
market access.,” Perspectives in Clinical Research ,
vol. 2(3), p. 112–3, 2011.
W. C. S. R. Jacobsen M, “GLP in nonclinical safety
testing.,” Fundamental and Applied Toxicology , vol.
(1), p. 59–63, 1996.
O. f. E. C.-o. a. D. (OECD), “. (2005). OECD Principles
of Good Laboratory Practice (GLP) – OECD Series on
Principles of Good Laboratory Practice and Compliance
Monitoring, No. 1.”.
G. Vogel, “FDA Inspections Find Serious Violations of
Good Laboratory Practices,” Science, vol. 334(6063),
pp. 1662-1663, 2011.
B. Deer, “How the case against the MMR vaccine was
fixed.,” BMJ, vol. 342, p. c5347, 2011.
G. D. &. M. S. Curfman, “Peer review in the balance.,”
New England Journal of Medicine, vol. 351(3), pp.
-199, 2004.
D. B. Resnik, “What is Ethics in Research & Why is
it Important?,” National Institute of Environmental
Health Sciences., 2017.
D. Fanelli, “How Many Scientists Fabricate and Falsify
Research? A Systematic Review and Meta-Analysis of
Survey Data.,” PLoS One, vol. 4(5), p. e5738, 2009.
A. E. &. R. D. B. Shamoo, “Responsible Conduct of
Research (3rd ed.),” Oxford University Press, 2015.
J. Carreyrou, “Bad Blood: Secrets and Lies in a Silicon
Valley Startup.,” 2018.
F. S. J. &. M. H. Godlee, “Wakefield’s article linking
MMR vaccine and autism was fraudulent,” BMJ (Clinical
research ed.), vol. 342, p. c7452, 2011.
D. Cyranoski, “STAP stem-cell papers: Nature issues
editorial note on controversial studies,” Nature, vol.
(7485), pp. 596-597, 2014 .
O. f. E. C.-o. a. Development, “OECD Series on
Principles of Good Laboratory Practice and Compliance
MonitoringNumber 19: Guidance Document on the GLP
Requirements for Peer Review of Histopathology.,”
OECD Publishing, 2016.
U. F. a. D. Administration, “Good Laboratory Practice
for Nonclinical Laboratory Studies,” Code of Federal
Regulations, vol. 58, 2001.
N. A. o. E. a. I. o. M. National Academy of Sciences,
“On Being a Scientist: A Guide to Responsible Conduct
in Research (3rd ed.),” The National Academies Press,
J. E. &. W. K. Johnson, “Enhancing transparency and
accountability in laboratory research,” Laboratory
Animal Science Professional, vol. 5(1), pp. 1-6, 2019 .
N. I. o. H. (NIH), “Promoting Transparency and
Reproducibility in Biomedical Research.,” 2018.
E. M. A. (EMA), “Reflection paper on the promotion
of good laboratory practice and non-clinical data
transparency,” 2016.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Drug Discovery and Development ( ISSN:2581-6861)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
